How the Dow's Pharma Stocks Helped Boost Markets Friday

Merck and Johnson & Johnson both pushed higher, helping the Dow recover from Thursday's weakness.

Jul 18, 2014 at 9:04PM

The Dow Jones Industrials (DJINDICES:^DJI) closed the week on a high note, rising 123 points Friday, and regaining most of the ground the Dow lost on Thursday. Investors decided that they had overreacted to news that a commercial airliner was shot down over Ukraine, and even though geopolitical risk remains in the forefront, favorable earnings and encouraging economic conditions continue to buoy the stock market higher. Moreover, Merck (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) both had good gains today, as investors look to the pharmaceutical sector as a potential growth industry despite its reputation as a solid income-producing business.

Source: Johnson & Johnson.

Johnson & Johnson's gains of nearly 1.5% led the Dow higher. Johnson & Johnson has a wide range of businesses, including its consumer over-the-counter products and its medical device unit; but pharmaceuticals have been its largest source of growth in recent years, and is now the largest segment under J&J's corporate umbrella. Even as Johnson & Johnson has to worry about the loss of patent protection on some of its older treatments, newer drugs, like psoriasis-fighter Stelara and anti-coagulant Xarelto, have picked up the slack with extraordinary sales growth recently.

Mrk Vaccine

Source: Merck.

Merck also rose, picking up 1.25%. Unlike Johnson & Johnson, Merck has been more active in focusing on pharmaceuticals, selling its consumer unit to Bayer for $14 billion, and contemplating other strategic moves to target greater growth in its pharma segment. With ample cash on hand, Merck can look at making acquisitions of its own, potentially boosting its pipeline prospects without the uncertainty of developing new drugs from scratch.

Yet, the overarching factor that's likely behind gains in Johnson & Johnson and Merck is rival Abbvie and news today of its acquisition of Shire. A rash of proposed deals in the pharmaceutical space have centered on the desirability for U.S. companies of finding large acquisition targets overseas in areas with more favorable corporate taxation. Finding a target large enough to make a successful tax inversion possible would be a big challenge for Merck or Johnson & Johnson, and the potential political fallout could be devastating to the Dow components. Nevertheless, with billions in taxes at stake, you can expect the trend toward tax-inversion transactions to continue.

Pharmaceutical companies, both within the Dow Jones Industrials and outside the Dow, are finally starting to grow again after dealing in some cases with devastating patent-cliff issues. As long as big pharma stocks don't overpay for acquisitions in an environment in which Fed Chair Janet Yellen specifically called out biotech stocks as having stretched valuations, the prospects for Merck, Johnson & Johnson, and other major pharma companies continue to look favorable.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers